BC404-UCART

BC404-UCART is an **allogeneic (universal) chimeric antigen receptor T cell (UCAR-T) therapy** engineered to target B cell maturation antigen (**BCMA**) on multiple myeloma cells and is further engineered to **secrete a CD47-SIRPα immune checkpoint blocker**. Using a CRISPR/Cas9 gene-editing system, donor T cells are modified to express a BCMA-specific CAR, and to continuously secrete an anti-CD47 nanobody fusion protein (hu404-hfc). This dual mechanism allows BC404-UCART not only to directly kill BCMA-positive multiple myeloma cells but also to promote phagocytosis of tumor cells by blocking the "don't eat me" signal between tumor cell CD47 and macrophage SIRPα, thus augmenting innate immune clearance. It is designed as an off-the-shelf immunotherapy approach for relapsed or refractory multiple myeloma[1].